This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials.
Curebase has raised $40 million in second-round financing that will help it run more complex interventional trials for its biopharma clients, according to chief executive Tom Lemberg.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.